

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PFIZER, INC. and  
SAMSUNG BIOEPIS CO., LTD.,<sup>1</sup>  
Petitioners,

v.

GENENTECH, INC.,  
Patent Owner,

---

IPR2017-01489  
Patent No. 6,407,213

---

**PETITIONER PFIZER'S UPDATED MANDATORY NOTICES**

---

<sup>1</sup> Samsung Bioepis Co., Ltd.'s IPR2017-02140 has been joined with this proceeding. (IPR2017-02140, Paper 40.)

IPR2017-01489

Petitioner Pfizer's Updated Mandatory Notices

In accordance with 37 C.F.R. §§ 42.8(a)(3) and (b)(2), Petitioner Pfizer hereby submits the following updated mandatory notices:

**A. 37 C.F.R. § 42.8(b)(2): Related Matters**

Petitioner concurrently filed an IPR petition for claims of U.S. Patent No. 6,407,213 (IPR2017-01488).

The '213 patent is the subject of two earlier IPR proceedings filed by third-party Mylan Pharmaceuticals Inc.: IPR2016-01693 and IPR2016-01694. These proceedings were terminated by the Board on March 10, 2017 after the parties filed a Joint Motion to Terminate. Paper No. 24, IPR2016-01693; Paper No. 23, IPR2016-01694 (March 10, 2017). The '213 patent is also the subject of two other earlier IPR proceedings filed by third-party Boehringer Ingelheim Pharmaceuticals, Inc.: IPR2017-02031 and IPR2017-02032. These proceedings were terminated by the Board on July 31, 2018 pursuant to a request for adverse judgment by the Petitioner in those cases.

The '213 patent is also the subject of IPR2017-01373, IPR2017-01374, IPR2017-02139, and IPR2017-02140. Petitioner is not a party to those proceedings.

The '213 patent is also at issue in *Genentech, Inc. et al. v. Amgen Inc.*, No. 1-17-cv-01407 (D. Del.); *Genentech, Inc. et al. v. Amgen Inc.*, No. 1-17-cv-01471 (D. Del.); *Celltrion, Inc. et al. v. Genentech, Inc. et al.*, No. 4-18-cv-00274 (N.D. Cal.); *Celltrion Inc. et al. v. Genentech, Inc. et al.* No. 2018-2160 (Fed. Cir.); *Genentech,*

IPR2017-01489

Petitioner Pfizer's Updated Mandatory Notices

*Inc. et al. v. Celltrion, Inc. et al.*, No. 1-18-cv-00095 (D. Del.); *Genentech, Inc. et al. v. Amgen, Inc.*, No. 1-18-cv-00924 (D. Del.); *Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd.*, No. 1-18-cv-01363 (D. Del.); and *Genentech, Inc. et al. v. Celltrion, Inc. et al.*, No. 1-18-cv-01025(D. Del.). Petitioner is not a party to these proceedings.

Patent Owner has asserted the '213 patent against Petitioner in *Genentech, Inc. v. Pfizer, Inc.*, No. 1-17-cv-01672 (D. Del.), filed November 17, 2017.

Petitioner is not aware of any other judicial or administrative matters that would affect, or be affected by, a decision in the proceeding.

Date: September 25, 2018

Respectfully submitted,

/Amanda Hollis/

Amanda Hollis (Reg. No. 55,629)

*Attorney For Petitioner Pfizer, Inc.*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing Updated Notices was served on September 25, 2018, via electronic service on lead and back-up counsel:

**For Genentech, Inc.**

david.cavanaugh@wilmerhale.com

lauren.blakely@wilmerhale.com

robert.gunther@wilmerhale.com

abrausa@durietangri.com

ddurie@durietangri.com

andrew.danford@wilmerhale.com

kevin.prussia@wilmerhale.com

lisa.pirozzolo@wilmerhale.com

**For Samsung Bioepis Co., Ltd.:**

ddrivas@whitecase.com

sweingaertner@whitecase.com

eric.majchrzak@whitecase.com

athakore@whitecase.com

*/Amanda Hollis/*  
Amanda Hollis